Henrik Stage, ADCendo CEO

The biotech craze hits the Nordics, dri­ving a record-high $62M Se­ries A for a Copen­hagen-based ADC play­er

With the biotech boom in the US in full swing, more mon­ey than ever is flow­ing in­to the in­dus­try — but that gush­er hasn’t ful­ly trans­lat­ed across the pond. Now, a Dan­ish biotech with some big-name back­ers has scored a record-high ear­ly fundrais­ing round. Is it a one-off or a sign of things to come?

Copen­hagen-based AD­Cen­do has bagged a $62 mil­lion Se­ries A round — the largest ever of its kind for a Dan­ish biotech — to ad­vance its pipeline of an­ti­body-drug con­ju­gates tar­get­ing uP­ARAP, a col­la­gen scav­enger re­cep­tor on some tu­mor cells, the com­pa­ny said Thurs­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.